 Zidovudine response pneumococcal vaccine persons AIDS AIDS-related complex Antibody pneumococcal vaccine individuals human immunodeficiency virus HIV asymptomatic infection AIDS AIDS-related complex ARC treatment zidovudine untreated AIDS/ARC patients Antibody responses asymptomatic persons aggregate geometric mean ng antibody nitrogen AbN AIDS/ARC patients median weeks range zidovudine therapy mean ng AbN/ml untreated AIDS/ARC patients Antibody zidovudine-treated AIDS/ARC patients independent dose mean mg/day range mg duration zidovudine therapy zidovudine-treated AIDS/ARC patients persistence aggregate antibody response months vaccination survival months vaccination response Pneumococcal vaccine early possible course HIV infection Immunization weeks AIDS/ARC patients zidovudine therapy